All lobbying filings

The Consilio Group

The Consilio Group filed a Q1 termination report for N Brereton Medical Technologies on April 15, 2026.

Lobbying for N Brereton Medical Technologies · Opiod prevention through a titration-based methodology.

As filed: THE CONSILIO GROUP for N BRERETON MEDICAL TECHNOLOGIES.

All filings by The Consilio Group · Everything N Brereton Medical Technologies has reported

Filing · LD-2 quarterly report Q1 termination

Reporting period

1st Quarter 2026

Jan 1 - Mar 31 · Posted Apr 15, 2026

Money reported

None

Registrations and no-activity reports carry no figure.

Client based in

Virginia

Representation ended

Jan 1, 2026

The registrant reported terminating its work for this client.

Official filing document

Lobbyists on this filing 2

OLIVER MEISSNER

Previously held: CEO
BRANDON KIRBY

Previously held: Director of Government Relations

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

Government bodies contacted 4

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 1

Alcohol and Drug Abuse

FenBlock is a patented, non-invasive medical device designed to help patients safely taper off prescribed fentanyl patches by gradually reducing the amount of medication absorbed through the skin.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.